- Home
- OTLK
as 11-22-2024 4:00pm EST
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | ISELIN |
| Market Cap: | 121.8M | IPO Year: | 2016 |
| Target Price: | $48.20 | AVG Volume (30 days): | 243.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.93 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.61 - $12.85 | Next Earning Date: | 12-20-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Outlook Therapeutics Inc. (OTLK)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| KENYON LAWRENCE A | OTLK | Chief Financial Officer | Sep 26 '24 | Buy | $5.69 | 5,000 | $28,446.00 | 5,946 |
Latest Outlook Therapeutics Inc. News
OTLK Breaking Stock News: Dive into OTLK Ticker-Specific Updates for Smart Investing
GlobeNewswire
17 days ago
Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference
GlobeNewswire
a month ago
Outlook Therapeutics® Participates in a Virtual Investor CEO Connect Segment
Argus Research
2 months ago
Daily – Vickers Top Buyers & Sellers for 10/01/2024
GlobeNewswire
2 months ago
Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series
GlobeNewswire
2 months ago
Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series
GlobeNewswire
3 months ago
Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial
GlobeNewswire
3 months ago
Outlook Therapeutics® to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Thomson Reuters StreetEvents
3 months ago
Q3 2024 Outlook Therapeutics Inc Earnings Call
Compare OTLK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OTLK Outlook Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.